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Inconsistency can be thought of as a conflict between 
“direct” evidence on a comparison between treatments B 
and C and “indirect” evidence gained from AC and AB trials. 
Like heterogeneity, inconsistency is caused by effect modifi-
ers and specifically by an imbalance in the distribution of 
effect modifiers in the direct and indirect evidence. Defining 
inconsistency as a property of loops of evidence, the relation 
between inconsistency and heterogeneity and the difficulties 
created by multiarm trials are described. We set out an 
approach to assessing consistency in 3-treatment triangular 
networks and in larger circuit  structures, its extension to cer-
tain special structures in which independent tests for incon-
sistencies can be created, and describe methods suitable for 
more complex networks. Sample WinBUGS code is given in 
an appendix. Steps that can be taken to minimize the risk of 
drawing incorrect conclusions from indirect comparisons 
and network meta-analysis are the same steps that will mini-
mize heterogeneity in pairwise meta-analysis. Empirical indi-
cators that can provide reassurance and the question of how 
to respond to inconsistency are also discussed. Key words: 
Network meta-analysis; inconsistency, indirect evidence, 
Bayesian. (Med Decis Making 2013;33:641–656)
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INTRODUCTION
Network meta-analysis (NMA), also referred to as 
mixed treatment comparisons or multiple treatment 
meta-analysis, combines information from multiple 
randomized comparisons of treatments A versus B, 
A versus C, B versus C, A versus D, and so on,1–6 
while preserving randomization.7 Given a connected 
network of comparisons, NMA produces an inter-
nally coherent set of estimates of the efficacy of any 
treatment in the network relative to any other, under 
the key assumption of evidence consistency. This 
requires that in every trial i in the network, regard-
less of the actual treatments that were compared, the 
true effect diXY of treatment Y relative to treatment X 
is the same in a fixed effects (FE) model, i.e., diXY = 
dXY, or exchangeable between trials in a random 
effects (RE) model, i.e., diXY ~ Normal(dXY, s
2). From 
this assumption, the consistency equations can be 
deduced,6,8–10 asserting that for any 3 treatments X, 
Y, Z, the FE, or mean effects in an RE model, are 
related as follows: dYZ = dXZ – dXY.
Where doubts have been expressed about NMA, 
these have focused on the consistency equations.11,12 
This is because, unlike the exchangeability assump-
tions from which they are derived, which are noto-
riously difficult to verify, the consistency equations 
offer a prediction about relationships in the data 
that can be statistically tested. Note that consist-
ency concerns the relation between the treatment 
contrasts whereas heterogeneity concerns the varia-
tion between trials within each contrast (we use 
contrast to refer to a pairwise comparison between 
2 treatments).
Received 13 June 2011 from the School of Social and Community 
Medicine, University of Bristol, Bristol, UK (SD, NJW, DMC, GL, AEA), 
and Department of Health Sciences, University of Leicester, Leicester, 
UK (AJS). This series of tutorial papers was based on Technical 
Support Documents in Evidence Synthesis (available from http://www.
nicedsu.org.uk), which were prepared with funding from the NICE 
Decision Support Unit. The views, and any errors or omissions, 
expressed in this document are of the authors only. Revision accepted 
for publication 13 December 2011.
Address correspondence to Sofia Dias, School of Social and 
Community Medicine, University of Bristol, Canynge Hall, 39 Whatley 
Road, Bristol BS8 2PS, UK; e-mail: s.dias@bristol.ac.uk.
DOI:  10.1177/0272989X12455847
642  •  MEDICAL DECISION MAKING/JUL 2013
DIAS AND OTHERS
This tutorial suggests methods for detection of 
inconsistency in evidence networks, clarifies the 
measures that can be taken to minimize the risk of 
drawing incorrect conclusions from indirect com-
parisons and NMA, and suggests some empirical 
indicators that might help assess what that risk 
might be. Sample code using the WinBUGS 1.4.3 
package13 is set out in the appendix.
This tutorial should be seen as an adjunct to Dias 
and others,10 which sets out a generalized linear 
modeling framework for NMA, indirect compari-
sons, and pairwise meta-analysis and explains how 
the same core model can be applied with different 
likelihoods and linking functions. It should be 
understood that this carries over entirely to the 
Bayesian models for inconsistency.
NETWORK STRUCTURE
Evidence Loops
The first step in checking for inconsistency is to 
examine network diagrams carefully, as the struc-
ture can reveal particular features that may assist in 
the choice of analysis method. We begin by consid-
ering networks that consist only of 2-arm trials, start-
ing with a triangular network ABC (Figure 1a), in 
which each edge represents direct evidence compar-
ing the treatments it connects. Taking treatment A as 
our reference treatment, a consistency model8,10 has 
2 basic parameters, say dAB and dAC, but we have data 
on 3 contrasts, dAB, dAC, and dBC. The latter, however, 
is not an independent parameter but is wholly deter-
mined by the 2 other parameters through the consist-
ency equations. Setting aside the question of the 
number of trials informing each pairwise contrast, 
we can see that there are 2 independent parameters 
to estimate and 3 sources of data. This generates 1 
degree of freedom with which to detect inconsist-
ency. Thus, if all trials are 2-arm trials, the inconsist-
ency degrees of freedom (ICDF) can be calculated 
from the number of treatments (nt) and the number 
of contrasts (N) on which there is evidence as6
ICDF = N – (nt – 1).
This accords with the commonsense notion of 
inconsistency, which views it as a property of loops 
of evidence.14,15 Every additional independent loop 
in a network of 2-arm trials represents 1 additional 
ICDF and one further way in which potential incon-
sistency can be realized.
In the square network in Figure 1b, there are N = 
4 independent pieces of evidence, nt = 4 treatments, 
and nt – 1 = 3 parameters in a consistency model, 
giving ICDF = 4 – (4 – 1) = 1. In Figure 1c, there are 
N = 9 contrasts on which there is evidence, nt = 7 
treatments, and 6 parameters, giving ICDF = 3. Note 
that the ICDF is equal to the number of independent 
loops. In Figure 1c, there are 2 separate structures in 
which inconsistency could be detected: the triangle 
EFG and the square ABCD. In the square, one could 
count a total of 3 loops: ABC, BCD, and ABCD. 
However, there are only 2 independent loops in this 
part of the structure: If we know all the edges of 
any 2 loops, we immediately know the edges of the 
third. Therefore, there can be only 2 inconsistencies 
in the ABCD square. Similarly, in Figure 1d, one can 
count a total of 7 loops: 4 three-treatment loops 
(ACD, BCD, ABD, ABC) and 3 four-treatment loops 
(ABCD, ACDB, CABD). But there are only 3 inde-
pendent loops: N = 6, nt = 4, and ICDF = 3. It is not 
possible to specify which loops are independent, 
only how many there are because knowing the edges 
of any 3 loops will mean we know the edges of the 
others.
Multiarm Trials
When multiarm trials (i.e., trials with more than 2 
arms) are included in the network, the definition of 
inconsistency becomes more complex. A 3-arm trial 
provides evidence on all 3 edges of an ABC triangle, 
and yet it cannot be inconsistent. In other words, 
although trial i estimates 3 parameters, di,AB, di,AC, 
b) N= 4, nt=4, ICDF=1  
A
B
D
C
d) N= 6, nt=4, ICDF=3 
A
B
C
D
a) N= 3, nt=3, ICDF=1 
A
B
C
c) N= 9, nt=7, ICDF=3 
A
B
D
C
E
F
G
Figure 1 Possible treatment networks: treatments are repre-
sented by letters; lines connecting 2 treatments indicate that a 
comparison between these treatments has been made (in 1 or 
more randomized controlled trials).
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di,BC, only 2 are independent because di,BC = di,AC – 
di,AB. There can therefore be no inconsistency within 
a 3-arm trial. Similarly, if all the evidence was from 
3-arm trials on the same 3 treatments, there could be 
no inconsistency, only between-trials heterogeneity.
The difficulty in defining inconsistency comes 
when we have 2- and 3-arm trial evidence, for exam-
ple, AB, AC, BC, and ABC trials. Because ICDF cor-
responds to the number of independent loops, if a 
loop is formed from a multiarm trial alone, it is not 
counted as an independent loop and must therefore 
be discounted from the total ICDF.6 Thus, where 
there are mixtures of 2-arm and multiarm trials, our 
definition of inconsistency as arising in loops cre-
ates inherent technical difficulties that cannot, as far 
as is known, be avoided.
TESTING FOR INCONSISTENCY
A key consideration in consistency assessment is 
whether independent tests for inconsistency can be 
constructed. These should be used wherever possi-
ble as they provide the simplest, most complete, and 
easiest to interpret analyses of inconsistency. We 
show how to construct independent tests, explain 
the circumstances where this is not possible, and set 
out methods for the more general case, which can be 
applied to any network.
Bucher Method for Single Loops of Evidence
The simplest method for testing consistency of 
evidence is essentially a 2-stage method.16 The first 
stage is to separately synthesize the evidence in each 
pairwise contrast; the second stage is to test whether 
direct and indirect evidence are in conflict. A direct 
estimate of the C versus B effect, dˆDir
BC
, is compared 
with an indirect estimate, dˆInd
BC
, formed from the AB 
and AC direct evidence
 dˆ
Ind
BC  = dˆ
Dir
AC  – dˆ
Dir
AB
.  (1)
The direct estimates can be either from individual 
trials or from pairwise meta-analyses, whether fixed 
or random effects. Attached to each direct estimate 
is a variance, for example, Var(dˆ Dir
BC
). As the direct 
estimates are statistically independent, we have 
Var(dˆInd
BC
) = Var(dˆ
Dir
AC
) – Var(dˆ
Dir
AB
).
Estimates of the inconsistency, w, and its variance 
can be formed by subtracting the direct and indirect 
estimates:
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An approximate test of the null hypothesis that 
there is no inconsistency is obtained by referring 
zBC
BC
BC
=
ˆ
ˆ )
ω
ωVar(
 to the standard normal distribution.
It makes no difference whether we compare the 
direct BC evidence to the indirect evidence formed 
through AB and AC, or compare the direct AB evi-
dence to the indirect AC and BC, or compare the AC 
with the AB and BC. The absolute values of the 
inconsistency estimates will be identical, as will the 
variances. This agrees with the intuition that, in a 
single loop, there can be only 1 inconsistency. 
However, this method can only be applied to 3 inde-
pendent sources of data. Three-arm trials cannot be 
included because they are internally consistent and 
will reduce the chances of detecting inconsistency.
This method generalizes naturally to the square 
network in Figure 1b, which, like the triangle and 
any other simple circuit structure, has ICDF = 1. An 
indirect estimate of any edge can be formed from the 
remaining edges, and the variance of the inconsist-
ency term is the sum of the variances of all the com-
parisons. For example, an indirect estimate dˆ Ind
BD
 can 
be formed as dˆ Ind
BD  = dˆ
Dir
AC  – dˆ
Dir
AB – dˆ
Dir
CD
, by successive 
application of the consistency equations. Clearly, as 
the number of edges in the loop increases, it becomes 
less and less likely that a real inconsistency will be 
detected because of the higher variance of the incon-
sistency estimate.
Extension to networks with multiple loops. Figure 
1c represents a further pattern in which the 
inconsistency analysis can be broken down into 
separate independent elements: There are a total of 
3 independent loops, and ICDF = 9 – (7 – 1) = 3. In 
this case, one inconsistency relates to the loop EFG, 
where there are 2 sources of evidence on any edge, 
whereas the other concerns the edge BC, on which 
there are 3 independent sources of evidence, 1 
direct and 2 indirect. To analyze inconsistency in 
this structure, the problem is broken down into 2 
separate and unrelated components. First, 
inconsistency in the EFG triangle is examined using 
the simple Bucher approach. Second, consistency 
between the 3 sources of evidence on the BC edge is 
examined by calculating a statistic to refer to a χ22 
distribution.17 These 2 independent tests provide a 
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complete analysis of the inconsistency in this 
network.
These methods are based on 2-arm trials. Inclusion 
of multiarm trials will lower their power to detect 
inconsistency. Our suggestion is that when a test on 
a loop ABC is being constructed, evidence from 
3-arm ABC trials is excluded. However, ABC evi-
dence on AB should be included when testing, for 
example, the ABD loop.
Methods for General Networks
Figure 1d shows a 4-treatment network in which 
there are data on every contrast and 3 possible incon-
sistencies. The difference between the networks in 
Figure 1d and Figure 1c is that in the former, there 
are 4 three-treatment loops (ACD, BCD, ABD, ABC) 
and 3 four-treatment loops (ABCD, ACDB, CABD), 
but these loops are not statistically independent. It is 
therefore not possible to construct a set of independ-
ent tests to examine the 3 inconsistencies.
Applying the Bucher method to each of the 7 
loops in the network in turn would be a simple way 
to check inconsistency in this network. However, 
the number of loops, and hence the number of tests 
carried out, will far exceed the maximum number of 
possible inconsistencies in the network. For exam-
ple, in a network where N = 42, nt = 12, and ICDF = 
31,18 repeated use of the Bucher method on each of 
the 3-way loops in this network gave 70 estimates of 
inconsistency for the response outcome and 63 esti-
mates for the acceptability outcome. In total, 6 loops 
showed statistically significant inconsistency, and 
the authors concluded that this was compatible with 
chance as 133 separate tests were performed. 
However, this could be questioned on the grounds 
that the 133 tests were not independent; there could 
not be more than 62 independent tests, and even this 
assumes that the 2 outcomes are unrelated.
Difficulties in the interpretation of statistical tests 
arise if any of the loops show significant inconsist-
ency, at say a P < 0.05 level. One cannot immediately 
reject the null hypothesis at this level because multi-
ple testing has taken place, and adjustment of signifi-
cance levels would need to be considered. However, 
because the tests are not independent, calculating the 
correct level of adjustment becomes a complex task. 
Furthermore, in networks with multiple treatments, 
the total number of triangular, quadrilateral, and 
higher-order loops may be extremely large.
Unrelated mean effects model. In complex 
networks, where independent tests cannot be 
constructed, we propose that the standard 
consistency model8,10 is compared with a model not 
assuming consistency. In the consistency model, a 
network with nt treatments, A, B, C, … defines nt – 1 
basic parameters19 dAB, dAC, …, which estimate the 
effects of all treatments relative to treatment A, 
chosen as the reference treatment. Prior distributions 
are placed on these parameters. All other contrasts 
can be defined as functions of the basic parameters 
by making the consistency assumption.
We propose an unrelated mean effects (UME) 
model in which each of the N contrasts for which 
evidence is available represents a separate, unre-
lated, basic parameter to be estimated: no consist-
ency is assumed. This model has also been termed 
inconsistency model.9,20,21
Formally, suppose we have a set of M trials com-
paring nt = 4 treatments, A, B, C, and D, in any con-
nected network. In an RE model, the study-specific 
treatment effects for a study comparing a treatment 
X to another treatment Y, di,XY, are assumed to follow 
a normal distribution
δ σi XY XYN d i M, ~ ( , ) ,..., .
2 1   for  =  (2)
In a consistency model, nt – 1 = 3 basic parame-
ters are given vague priors: dAB, dAC, dAD ~N(0,100
2), 
and the consistency equations define all other pos-
sible contrasts as
d d d
d d d
d d d
BC AC AB
BD AD AB
CD AD AC
= −
= −
= − .
 (3)
In an RE UME model, each of the mean treatment 
effects in equation 2 is treated as a separate (inde-
pendent) parameter to be estimated, sharing a com-
mon variance s2. So, for the network in Figure 1d, 
the 6 treatment effects are all given vague priors: dAB, 
dAC, dAD, dBC, dBD, dCD ~ N(0,100
2). Note that the extra 
number of parameters in this model is equal to the 
ICDF.
In an FE UME model, no shared variance param-
eter needs to be considered. The model is then 
equivalent to performing completely separate pair-
wise meta-analyses of the contrasts. However, fitting 
a UME model to all the data has the advantage of 
easily accommodating multiarm trials as well as 
providing a single global measure of model fit.
When multiarm trials are included in the evi-
dence, the UME model can have different parame-
terizations depending on which of the multiple 
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contrasts defined by a multiarm trial are chosen. For 
example, a 3-arm trial ABC can inform the AB and 
AC independent effects, or it can be chosen to 
inform the AB and BC effects (if B was the reference 
treatment), or the AC and BC effects (with C as refer-
ence). The code presented in the appendix arbitrar-
ily chooses the contrasts relative to the first treatment 
in the trial. Thus, ABC trials inform the AB and AC 
contrasts, BCD trials inform BC and BD, and so 
forth. For FE models, the choice of parameterization 
makes no difference to the results, but in the RE 
model, the choice of parameterization will affect 
both the heterogeneity estimate and the tests of 
inconsistency.
Illustrative Examples
Smoking cessation. Twenty-four studies, including 
2 three-arm trials, compared 4 smoking cessation 
counseling programs and recorded the number of 
individuals with successful smoking cessation at 6 
to 12 mo.3,6 All possible contrasts were compared, 
forming the network in Figure 1d, where A = no 
intervention, B = self-help, C = individual counseling, 
and D = group counseling.
We contrast a consistency model8,10 with an RE 
model estimating 6 independent mean treatment 
effects. Results for both models are presented in 
Table 1, along with the posterior mean of the 
residual deviance and deviance information crite-
rion (DIC), measures to assess model fit.22 
Comparison between the deviance and DIC statis-
tics of the consistency and UME models provides 
an omnibus test of consistency. In this case, the 
heterogeneity estimates, the posterior means of 
the residual deviance, and the DICs are very simi-
lar for both models.
Plotting the posterior mean deviance of the indi-
vidual data points in the UME model against their 
posterior mean deviance in the consistency model 
(Figure 2) provides information that can help iden-
tify the loops in which inconsistency is present. We 
expect each data point to have a posterior mean 
deviance contribution of about 1, with higher contri-
butions suggesting a poorly fitting model.22 In this 
example, the contributions to the deviance are very 
similar and close to 1 for both models. Two points 
have a higher than expected posterior mean 
 deviance—these are the arms of 2 trials that have a 
zero cell—but the higher deviance is seen in both 
models. In general, trial arms with zero cells will 
have a high deviance as the model will never predict 
a zero cell exactly. The parameter estimates are 
similar for both models, and there is considerable 
overlap in the 95% credible intervals. This suggests 
no evidence of inconsistency in the network.
Table 1 Smoking Example: Posterior Summaries from Random Effects Consistency and Unrelated Mean 
Effects Models
Network Meta-analysisa (Consistency Model) Unrelated Mean Effects Model
Mean/Median SD CrI Mean/Median SD CrI
dAB 0.49 0.40 (–0.29, 1.31) 0.34 0.58 (–0.81, 1.50)
dAC 0.84 0.24 (0.39, 1.34) 0.86 0.27 (0.34, 1.43)
dAD 1.10 0.44 (0.26, 2.00) 1.43 0.88 (–0.21, 3.29)
dBC 0.35 0.41 (–0.46, 1.18) –0.05 0.74 (–1.53, 1.42)
dBD 0.61 0.49 (–0.34, 1.59) 0.65 0.73 (–0.80, 2.12)
dCD 0.26 0.41 (–0.55, 1.09) 0.20 0.78 (–1.37, 1.73)
s 0.82 0.19 (0.55, 1.27) 0.89 0.22 (0.58, 1.45)
resdevb 54.0 53.4
pD 45.0 46.1
DIC 99.0 99.5
Note: Mean, standard deviation (SD), 95% credible interval (CrI) of relative treatment effects, and median of between-trial standard deviation (s) on the 
log-odds scale and posterior mean of the residual deviance (resdev), effective number of parameters (pD), and deviance information criterion. Results 
are based on 100 000 iterations on 3 chains after a burn-in period of 20 000 for the consistency model and after a burn-in of 30 000 for the inconsistency 
model. Treatments: A= no intervention, B = self-help, C = individual counseling, D = group counseling.
a. dBC, dBD, dCD calculated using the consistency equations.
b. Compare to 50 data points.
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Thrombolytic treatments. Figure 3 represents the 
treatment network for a data set consisting of 50 trials 
comparing 8 thrombolytic drugs and percutaneous 
transluminal coronary angioplasty, following acute 
myocardial infarction.23,24 Data consist of the number 
of deaths in 30 or 35 days and the number of patients 
in each treatment arm. Note that in this network, not 
all treatment contrasts have been compared in a trial. 
There are 9 treatments in total and information on 16 
pairwise comparisons, which would suggest an ICDF 
of 8. However, there is 1 loop, SK, Acc t-PA, SK+t-PA 
(highlighted in bold), which is only informed by a 
3-arm trial and therefore cannot contribute to the 
number of possible inconsistencies. Discounting this 
loop gives ICDF = 7.25
An FE NMA (consistency model) with a binomial 
likelihood and logit link8,10 was fitted to the data, 
taking SK as the reference treatment, that is, the 8 
treatment effects relative to SK are the basic param-
eters and have been estimated, whereas the remain-
ing relative effects were obtained from the consistency 
assumptions. An FE model without the consistency 
assumptions was also fitted, which estimated 15 
independent mean treatment effects (Table 2).
Although the UME model is a better fit (lower 
posterior mean of the residual deviance), the DICs 
are very similar for both models because the UME 
model has 7 more parameters than the NMA model 
does. A plot of the individual data points’ posterior 
mean deviance contribution in each of the 2 models 
highlights 4 data points that fit poorly to the consist-
ency model (Figure 4). These points correspond to 
the 2 arms of trials 44 and 45, which were the only 
2 trials comparing Acc t-PA to ASPAC. Furthermore, 
the posterior estimates of the treatment effects of 
ASPAC versus Acc t-PA (Table 2) in the consistency 
and UME models differ markedly. The fact that the 2 
trials on this contrast give similar results to 
each other but are in conflict with the remaining 
evidence supports the notion that there is a system-
atic inconsistency.
Other Methods for Detecting Inconsistency
Variance measures of inconsistency. In the UME 
models described above, a different basic parameter 
represents each contrast. One can reparameterize the 
6-parameter UME model so that instead of 6 
treatment effect parameters (dAB, dAC, dAD, dBC, dBD, 
dCD) we have (dAB, dAC, dAD, wBC, wBD, wCD), where
ω
ω
ω
BC BC AC AB
BD BD AD AB
CD CD AD AC
d d d
d d d
d d d
= − −
= − −
= − −





( )
( )
( )
.
The wBC, wBD, wCD parameters are the inconsisten-
cies between the direct and indirect evidence on 
these 3 edges. However, rather than considering the 
3 inconsistency parameters as unrelated, we might 
assume that they all come from a random dis-
tribution, for example, wXY, ~ N(0,s
2
w), where this 
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Figure 2 Plot of the individual data points’ posterior mean devi-
ance contributions for the consistency model (horizontal axis) 
and the unrelated mean effects model (vertical axis) along with 
the line of equality.
SK (1)
UK (8)
PTCA (7)
TNK (6)
r-PA (5)
SK + t-PA (4)
Acc t-PA (3) 
t-PA (2)
ASPAC (9)
Figure 3 Thrombolytics example network. Lines connecting 2 
treatments indicate that a comparison between these treatments 
(in 1 or more randomized controlled trials) has been made. The 
triangle highlighted in bold represents comparisons that have 
been made in only a 3-arm trial. Treatments: streptokinase (SK), 
alteplase (t-PA), accelerated alteplase (Acc t-PA), reteplase (r-PA), 
tenecteplase (TNK), urokinase (UK), anistreptilase (ASPAC), per-
cutaneous transluminal coronary angioplasty (PTCA).
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 additional between-contrast variance serves as a 
measure of inconsistency.6,15 We do not recommend 
this, however, because measures of variance will 
have very wide credible intervals unless the ICDF is 
extremely high. Even then, large numbers of large 
trials on each contrast would be required to obtain a 
meaningful estimate. Furthermore, where there is a 
single loop (ICDF = 1), it should be impossible to 
obtain any estimate of s2w. See Salanti and others
26 
for further comments on this issue.
Node splitting. A more sophisticated approach, 
which needs to be implemented in a Bayesian MCMC 
framework, is node splitting.25 This is a powerful 
and robust method that can be recommended as a 
further option for inconsistency analysis in complex 
networks. It allows the user to split the information 
contributing to estimates of a parameter (node), say, 
dXY, into 2 distinct components: the direct based on 
all the XY data (which may come from XY, XYZ, 
WXY trials) and the indirect based on all the 
remaining evidence. The process can be applied to 
any contrast (node) in the network and in networks 
of any complexity. Like the UME model above, a 
shared variance term solves the difficulties created 
in an RE model when some contrasts are supported 
by only 1 or 2 trials. Node splitting can also generate 
intuitive graphics showing the difference between 
the estimates based on direct, indirect, and combined 
evidence.
DISCUSSION
Although it is essential to carry out tests for 
inconsistency, this should not be considered in an 
overly mechanical way. Detection of inconsistency, 
like the detection of any statistical interaction, 
requires far more data than is needed to establish the 
presence of a treatment effect. The null hypothesis 
of consistency will therefore nearly always fail to be 
rejected, although this does not mean that there is no 
inconsistency.
The mechanisms that potentially could create 
bias in indirect comparisons appear be to identical 
to those that cause heterogeneity in pairwise meta-
analysis. Thus, to ensure that conclusions based on 
Table 2 Thrombolitics Example: Posterior Summaries, Mean, Standard Deviation (SD), and 95% Credible 
Interval (CrI) on the Log-Odds Ratio Scale for Treatments Y versus X for Contrasts That Are Informed by 
Direct Evidence and Posterior Mean of the Residual Deviance (resdev), Number of Parameters (pD), and 
DIC for the Fixed Effects Network Meta-analysis and Inconsistency Models
Treatment Network Meta-analysisa (Consistency Model) Unrelated Mean Effects Model
X Y Mean SD CrI Mean SD CrI
SK t-PA 0.002 0.030 (–0.06, 0.06) –0.004 0.030 (–0.06, 0.06)
SK Acc t-PA –0.177 0.043 (–0.26, –0.09) –0.158 0.049 (–0.25, –0.06)
SK SK + t-PA –0.049 0.046 (–0.14, 0.04) –0.044 0.047 (–0.14, 0.05)
SK r-PA –0.124 0.060 (–0.24, –0.01) –0.060 0.089 (–0.23, 0.11)
SK PTCA –0.173 0.077 (–0.32, –0.02) –0.665 0.185 (–1.03, –0.31)
SK UK –0.476 0.101 (–0.67, –0.28) –0.369 0.518 (–1.41, 0.63)
SK ASPAC –0.203 0.221 (–0.64, 0.23) 0.005 0.037 (–0.07, 0.08)
t-PA PTCA 0.016 0.037 (–0.06, 0.09) –0.544 0.417 (–1.38, 0.25)
t-PA UK –0.180 0.052 (–0.28, –0.08) –0.294 0.347 (–0.99, 0.37)
t-PA ASPAC –0.052 0.055 (–0.16, 0.06) –0.290 0.361 (–1.01, 0.41)
Acc t-PA r-PA –0.126 0.067 (–0.26, 0.01) 0.019 0.066 (–0.11, 0.15)
Acc t-PA TNK –0.175 0.082 (–0.34, –0.01) 0.006 0.064 (–0.12, 0.13)
Acc t-PA PTCA –0.478 0.104 (–0.68, –0.27) –0.216 0.119 (–0.45, 0.02)
Acc t-PA UK –0.206 0.221 (–0.64, 0.23) 0.146 0.358 (–0.54, 0.86)
Acc t-PA ASPAC 0.013 0.037 (–0.06, 0.09) 1.405 0.417 (0.63, 2.27)
resdevb 105.9 99.7
pD 58 65
DIC 163.9 164.7
Note: Results are based on 50 000 iterations on 2 chains after a burn-in period of 50 000 for the consistency model and after a burn-in of 20 000 for the 
inconsistency model. Treatments: streptokinase (SK), alteplase (t-PA), accelerated alteplase (Acc t-PA), reteplase (r-PA), tenecteplase (TNK), urokinase 
(UK), anistreptilase (ASPAC), percutaneous transluminal coronary angioplasty (PTCA).
a. All relative treatment effects not involving SK were calculated using the consistency equations.
b. Compare to 102 data points.
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indirect evidence are sound, we must attend to the 
direct evidence on which they are based, as is clear 
from equation 1. This states that if the direct esti-
mates of the AB and AC effects are unbiased esti-
mates of the treatment effects in the target population, 
the indirect estimate of the BC effect must be unbi-
ased as well. Conversely, any bias in the direct esti-
mates, for example, due to effect-modifying 
covariates arising from the patients not being drawn 
from the target population, will be passed on to the 
indirect estimates in equal measure. The term bias 
in this context must be seen broadly, comprising 
both internal and external threats to validity.27 So if 
the direct evidence on AB is based on trials con-
ducted on a patient population different from the 
target, and a treatment effect modifier is present, 
using the AB trials to draw inferences about the tar-
get population can be considered as (external) bias, 
which will be inherited by any indirect estimates 
based on these data.
Thus, the question, “Are conclusions based on 
indirect evidence reliable?” should be considered 
alongside the question, “Are conclusions based on 
pairwise meta-analysis reliable?” Any steps that can 
be taken to avoid between-trial heterogeneity will be 
effective in reducing the risk of drawing incorrect 
conclusions from pairwise meta-analysis, indirect 
comparisons, and NMA alike.
In the decision-making context, the most obvious 
sources of potential heterogeneity of effect, such as 
differences in dose or differences in cotherapies, 
will already have been eliminated when defining the 
scope, which is likely to restrict the set of trials to 
specific doses and cotherapies.
Clear cases in which direct and indirect evidence 
are in conflict are rare in the literature.14,28 Where 
inconsistency has been evident, it illustrates the 
danger introduced by heterogeneity and in particu-
lar by the practice of trying to combine evidence on 
disparate treatment doses or treatment combinations 
within meta-analyses, often termed lumping.1,29
The place for an enquiry into consistency is 
alongside a consideration of heterogeneity and its 
causes and, where appropriate, the reduction of het-
erogeneity through covariate adjustment (meta-
regression) and bias adjustment.27,30,31 This suggests 
that the risk of inconsistency is greatly reduced if 
between-trial heterogeneity is low. Empirical assess-
ment of heterogeneity can therefore provide some 
reassurance or alert investigators to the risk of incon-
sistency. Tests of homogeneity in the pairwise com-
parisons can be used, or the posterior summaries of 
the distribution of the between-trials standard devia-
tion can be compared to the size of the mean treat-
ment effects. A second useful indicator is the 
between-trials variation in the trial baselines. If the 
treatment arms representing placebo or a standard 
treatment have similar proportions of events, this 
suggests that the trial populations are relatively 
homogeneous and that there will be little heteroge-
neity in the treatment effects. If, on the other hand, 
the baselines are highly heterogeneous, there is a 
potential risk of heterogeneity in the relative effects. 
Heterogeneity in baselines can be examined via a 
Bayesian synthesis.32,33
One possible cause of inconsistency is a poor 
choice of scale of measurement, which can also lead 
to increased heterogeneity.20,34 It is not always obvi-
ous whether to model treatment effects on a risk 
difference, logit, or other scale. The choice of the 
most appropriate scale is essentially an empirical 
one, although there is seldom enough evidence to 
decide on the basis of goodness of fit.8,10
The choice of method used to test for inconsist-
ency should be guided by the evidence structure. If 
it is possible to construct independent tests, then the 
Bucher method or its extensions represent the most 
simple and complete approach. In more complex 
networks, a repeated application of the Bucher 
method to all the possible loops produces 
 interpretable results as long as no “significant” 
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Figure 4 Plot of the individual data points’ posterior mean devi-
ance contributions for the consistency model (horizontal axis) 
and the unrelated mean effects model (vertical axis) along with 
the line of equality. Points that have a better fit in the unrelated 
mean effects model have been marked with the trial number.
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inconsistencies are found. Each application of the 
Bucher method is a valid test at its stated signifi-
cance level. However, if inconsistencies are found 
when applying the test to all loops in the network, 
correction for multiple testing is needed, but it is 
difficult to specify how this should be done.
In networks where multiarm trials are included, 
assessment of inconsistency becomes more problem-
atic, as the presence of such internally consistent 
trials tends to hide potential inconsistencies. Our 
suggestion of removing multiarm trials involved in 
the loop being checked can become quite cumber-
some when there are multiple multiarm trials and 
multiple loops. Furthermore, removal of some trials 
may affect the estimated between-trials heterogene-
ity, which in turn may affect the detection of incon-
sistency. A careful examination of the network, 
paying special attention to which contrasts are 
informed by multiarm trials, how large these trials 
are, and how they are likely to affect estimates, is 
recommended. This can inform both the simple 
Bucher approach and the parameterization of the 
UME model.
Within a Bayesian framework, a consistency 
model can be compared with a model without the 
consistency assumptions. Analyses of residual devi-
ance can provide an omnibus test of global incon-
sistency and can also help locate it. Node splitting25 
is another effective method for comparing direct 
evidence to indirect evidence in complex networks, 
but measures of inconsistency variance6 or incoher-
ence variance15 are not recommended as indicators 
of inconsistency.
Although the Bucher approach is conceptually 
simpler and easy to apply, it requires 2 stages, 
whereas Bayesian approaches have the advantage of 
being one stage: There is no need to summarize the 
findings on each contrast first. The 2-stage approach 
introduces a particular difficulty in networks in 
which the evidence on some contrasts may be lim-
ited to a small number of trials. This is that the deci-
sion as to whether to fit an RE model must be taken 
for each contrast separately, and if there is only one 
study, only an FE analysis is available, even when 
there is clear evidence of heterogeneity on other 
contrasts. This causes a further problem: Under the 
null hypothesis of consistency that the method sets 
out to test, the true variances have to conform to 
special relationships known as “triangle inequali-
ties,”9 but separate estimation makes it hard to 
ensure these inequalities are met. The likelihood of 
detecting an inconsistency, therefore, will be highly 
sensitive to the pattern of evidence. The choice of FE 
or RE summaries in the first stage can determine 
whether inconsistency is detected in the second 
stage.17 Interestingly, the UME model with its shared 
variance parameter offers a way of smoothing the 
estimates of between-trial heterogeneity.
Sparse data also show drawbacks in the Bayesian 
methods, especially when an RE analysis is used. 
The difficulty is that the greater the degree of 
between-trials heterogeneity, the less likely it is for 
inconsistency to be detectable, but there is seldom 
enough data to estimate the between-trials variation. 
The practice of using vague prior distributions for 
the between-trials variation, combined with a lack of 
data, will generate posteriors that allow an unrealis-
tically high variance. This, in turn, is likely to mask 
all but the most obvious signs of inconsistency.
Although possible inconsistency should be inves-
tigated thoroughly, the preferred approach should be 
to consider potential sources of heterogeneity in 
advance.
Finally, there has been little work on how to 
respond to inconsistency when it is detected in a 
network. It is a reasonable principle that decisions 
should be based on models that are internally coher-
ent, that is, models in which dYZ = dXZ – dXY, and that 
these models should fit the data. If the data cannot 
be fitted by a coherent model, then some kind of 
adjustment must be made. Any adjustment in 
response to inconsistency is post hoc, and usually 
there will be a large number of different adjustments 
to the body of data that could eliminate the incon-
sistency. There are clear examples of this in the lit-
erature on multiparameter evidence synthesis in 
epidemiology applications,35,36 emphasizing the 
importance of identifying potential causes of hetero-
geneity of effect at the scoping stage and potential 
internal biases in advance of synthesis. Similarly, 
although inconsistency in one part of the network 
does not necessarily imply that the entire body of 
evidence is to be considered suspect, a reexamina-
tion of all included studies is desirable.
Inconsistency is not a property of individual stud-
ies but of loops of evidence, and it may not always 
be possible to isolate which loop is responsible for 
the detected inconsistency, let alone which edge.6 
Where several alternative adjustments are available, 
a sensitivity analysis is essential.
APPENDIX: winBUGS CODE FOR  
ILLUSTRATIVE EXAMPLES
Below, we set out code to fit random and fixed 
effects NMA and UME models to any network with 
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a binomial likelihood and logit link function. In Dias 
and others,8,10 a generalized linear model framework 
was introduced, with explanations of how the code 
for the binomial/logit model could be adapted for 
other likelihoods and link functions, including 
Poisson/log, Normal/identity, and other models. The 
models below can be adapted in exactly the same 
way.
The code below is fully general and will work for 
any number of multiarm trials with any number of 
arms. It is suitable for networks in which there is 
information on all possible treatment contrasts 
(such as in the smoking example presented in the 
article) or where there is information on just a sub-
set of possible contrasts (such as in the thrombo-
lytic treatments example in the article). However, in 
the latter case, the WinBUGS output from the UME 
model for contrasts that have no information will be 
redundant; that is, the posterior distribution will be 
equal to the prior, and no inferences can be made on 
these contrasts. We therefore recommend a careful 
consideration of the network structure before look-
ing at the WinBUGS output from the UME code 
below.
Smoking Cessation: Network Meta-analysis RE Model, Binomial Likelihood
# Binomial likelihood, logit link
# Random effects model for multi-arm trials
model{                                      # *** PROGRAM STARTS
for(i in 1:ns){                             # LOOP THROUGH STUDIES
    w[i,1] <- 0            # adjustment for multi-arm trials is zero for control arm
    delta[i,1] <- 0                    # treatment effect is zero for control arm
    mu[i] ~ dnorm(0,.0001)                 # vague priors for all trial baselines
    for (k in 1:na[i]) {                    # LOOP THROUGH ARMS
        r[i,k] ~ dbin(p[i,k],n[i,k])       # binomial likelihood
        logit(p[i,k]) <- mu[i] + delta[i,k]        # model for linear predictor
        rhat[i,k] <- p[i,k] * n[i,k]       # expected value of the numerators 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))         #Deviance contribution
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))         }
    resdev[i] <- sum(dev[i,1:na[i]])             #  summed residual deviance contribution for this trial
    for (k in 2:na[i]) {                    # LOOP THROUGH ARMS
        delta[i,k] ~ dnorm(md[i,k],taud[i,k])      # trial-specific LOR distributions
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]      # mean of LOR distributions (with multi-arm trial correction)
        taud[i,k] <- tau *2*(k-1)/k      # precision of LOR distributions (with multi-arm trial correction)
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])      # adjustment for multi-arm RCTs
        sw[i,k] <- sum(w[i,1:k-1])/(k-1)       # cumulative adjustment for multi-arm trials
      }
  }   
totresdev <- sum(resdev[])             # Total Residual Deviance
d[1]<-0           # treatment effect is zero for reference treatment
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }  # vague priors for treatment effects
sd ~ dunif(0,5)         # vague prior for between-trial SD
tau <- pow(sd,-2)       # between-trial precision = (1/between-trial variance)
# pairwise ORs and LORs for all possible pair-wise comparisons
for (c in 1:(nt-1)) {  
    for (k in (c+1):nt)  { 
        or[c,k] <- exp(d[k] - d[c])
        lor[c,k] <- (d[k]-d[c])
     }  
 }
}                                       # *** PROGRAM ENDS                          
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# Data (Smoking example) 
# nt=no. treatments, ns=no. studies
list(nt=4,ns=24 )
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[]
9 140 23 140 10 138 1 3 4 3  # trial 1 ACD
11 78 12 85 29 170 2 3 4 3 # trial 2 BCD
75 731 363 714 NA 1 1 3 NA 2 # 3
2 106 9 205 NA 1 1 3 NA 2 # 4
58 549 237 1561 NA 1 1 3 NA 2 # 5
0 33 9 48 NA 1 1 3 NA 2 # 6
3 100 31 98 NA 1 1 3 NA 2 # 7
1 31 26 95 NA 1 1 3 NA 2 # 8
6 39 17 77 NA 1 1 3 NA 2 # 9
79 702 77 694 NA 1 1 2 NA 2 # 10
18 671 21 535 NA 1 1 2 NA 2 # 11
64 642 107 761 NA 1 1 3 NA 2 # 12
5 62 8 90 NA 1 1 3 NA 2 # 13
20 234 34 237 NA 1 1 3 NA 2 # 14
0 20 9 20 NA 1 1 4 NA 2 # 15
8 116 19 149 NA 1 1 2 NA 2 # 16
95 1107 143 1031 NA 1 1 3 NA 2 # 17
15 187 36 504 NA 1 1 3 NA 2 # 18
78 584 73 675 NA 1 1 3 NA 2 # 19
69 1177 54 888 NA 1 1 3 NA 2 # 20
20 49 16 43 NA 1 2 3 NA 2 # 21
7 66 32 127 NA 1 2 4 NA 2 # 22
12 76 20 74 NA 1 3 4 NA 2 # 23
9 55 3 26 NA 1 3 4 NA 2 # 24
END
# Initial values
# Chain 1
list(sd=1,  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0) )
# Chain 2
list(sd=1.5,  mu=c(0,2,0,-1,0,  0,1,0,-1,0,  0,0,0,10,0,  0,10,0,0,0,  0,-2,0,0))
# Chain 3
list(sd=3,  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0))
Smoking Cessation: UME RE Model, Binomial Likelihood
# Binomial likelihood, logit link, unrelated mean effects model
# Random effects model
model{                                  # *** PROGRAM STARTS
for(i in 1:ns){                         # LOOP THROUGH STUDIES
    delta[i,1]<-0                       # treatment effect is zero in control arm
    mu[i] ~ dnorm(0,.0001)              # vague priors for trial baselines
    for (k in 1:na[i])  {               # LOOP THROUGH ARMS
        r[i,k] ~ dbin(p[i,k],n[i,k])            # binomial likelihood
        logit(p[i,k]) <- mu[i] + delta[i,k]             # model for linear predictor
        rhat[i,k] <- p[i,k] * n[i,k]          # expected value of the numerators 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))       #Deviance contribution
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          +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))   
      }
   resdev[i] <- sum(dev[i,1:na[i]])           # summed residual deviance contribution for this trial
    for (k in 2:na[i]) {  # LOOP THROUGH ARMS
        delta[i,k] ~ dnorm(d[t[i,1],t[i,k]] ,tau)        # trial-specific LOR distributions
      }
  }   
totresdev <- sum(resdev[])                   # Total Residual Deviance
for (c in 1:(nt-1)) {                   # priors for all mean treatment effects
    for (k in (c+1):nt)  { d[c,k] ~ dnorm(0,.0001) } 
  }  
sd ~ dunif(0,5)                   # vague prior for between-trial standard deviation
var <- pow(sd,2)                  # between-trial variance
tau <- 1/var                      # between-trial precision
}                   # *** PROGRAM ENDS
# Data is the same as for network meta-analysis model
#Initial values
# chain 1
list(sd=1,  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0), 
d = structure(.Data = c(NA,0,0,0,     NA, NA,0,0,      NA,NA,NA,0), .Dim = c(3,4)))
# chain 2
list(sd=1.5,  mu=c(0,2,0,-1,0,  0,1,0,-1,0,  0,0,0,10,0,  0,10,0,0,0,  0,-2,0,0),
d = structure(.Data = c(NA,-2,0,5,     NA, NA,0,2,      NA,NA,NA,5), .Dim = c(3,4)))
# chain 3
list(sd=3,  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0),
d = structure(.Data = c(NA,-3,-3,-3,     NA, NA,-3,-3,      NA,NA,NA,-3), .Dim = c(3,4)))
Thrombolytic Treatments: Network Meta-analysis FE Model, Binomial Likelihood
# Binomial likelihood, logit link
# Fixed effects model 
model{      # *** PROGRAM STARTS
for(i in 1:ns){      # LOOP THROUGH STUDIES
    mu[i] ~ dnorm(0,.0001)         # vague priors for all trial baselines
    for (k in 1:na[i])  {           # LOOP THROUGH ARMS
        r[i,k] ~ dbin(p[i,k],n[i,k])       # binomial likelihood
        logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]  # model for linear predictor
        rhat[i,k] <- p[i,k] * n[i,k]    # expected value of the numerators 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))  #Deviance contribution
             +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
      }
    resdev[i] <- sum(dev[i,1:na[i]])    # summed residual deviance contribution for this trial
     }   
totresdev <- sum(resdev[])         # Total Residual Deviance
d[1]<-0         # treatment effect is zero for reference treatment
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects
# pairwise ORs
for (c in 1:(nt-1)) {  
    for (k in (c+1):nt)  { 
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        or[c,k] <- exp(d[k] - d[c])
        lor[c,k]<-(d[k]-d[c])
      }  
  }
}                                                        # *** PROGRAM ENDS
# Data (Thrombolytic treatments example) 
#nt=no. treatments, ns=no. studies; 
list(nt=9,ns=50)
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[] # study ID
1472 20251 652 10396 723 10374 1 3 4 3 # 1
9 130 6 123 NA NA 1 2 NA 2 # 2
5 63 2 59 NA NA 1 2 NA 2 # 3
3 65 3 64 NA NA 1 2 NA 2 # 4
887 10396 929 10372 NA NA 1 2 NA 2 # 5
1455 13780 1418 13746 1448 13773 1 2 9 3 # 6
7 85 4 86 NA NA 1 2 NA 2 # 7
12 159 7 157 NA NA 1 2 NA 2 # 8
10 135 5 135 NA NA 1 2 NA 2 # 9
4 107 6 109 NA NA 1 4 NA 2 # 10
285 3004 270 3006 NA NA 1 5 NA 2 # 11
11 149 2 152 NA NA 1 7 NA 2 # 12
1 50 3 50 NA NA 1 7 NA 2 # 13
8 58 5 54 NA NA 1 7 NA 2 # 14
1 53 1 47 NA NA 1 7 NA 2 # 15
4 45 0 42 NA NA 1 7 NA 2 # 16
14 99 7 101 NA NA 1 7 NA 2 # 17
9 41 3 46 NA NA 1 7 NA 2 # 18
42 421 29 429 NA NA 1 7 NA 2 # 19
2 44 3 46 NA NA 2 7 NA 2 # 20
13 200 5 195 NA NA 2 7 NA 2 # 21
2 56 2 47 NA NA 2 7 NA 2 # 22
3 55 1 55 NA NA 3 7 NA 2 # 23
10 94 3 95 NA NA 3 7 NA 2 # 24
40 573 32 565 NA NA 3 7 NA 2 # 25
2 61 3 62 NA NA 3 7 NA 2 # 26
16 419 20 421 NA NA 3 7 NA 2 # 27
5 69 3 71 NA NA 3 7 NA 2 # 28
5 75 5 75 NA NA 3 7 NA 2 # 29
59 782 52 790 NA NA 3 7 NA 2 # 30
5 81 2 81 NA NA 3 7 NA 2 # 31
16 226 12 225 NA NA 3 7 NA 2 # 32
8 66 6 71 NA NA 3 7 NA 2 # 33
522 8488 523 8461 NA NA 3 6 NA 2 # 34
356 4921 757 10138 NA NA 3 5 NA 2 # 35
13 155 7 169 NA NA 3 5 NA 2 # 36
10 203 7 198 NA NA 1 8 NA 2 # 37
3 58 2 52 NA NA 1 9 NA 2 # 38
3 86 6 89 NA NA 1 9 NA 2 # 39
3 58 2 58 NA NA 1 9 NA 2 # 40
13 182 11 188 NA NA 1 9 NA 2 # 41
2 26 7 54 NA NA 3 8 NA 2 # 42
12 268 16 350 NA NA 3 8 NA 2 # 43
5 210 17 211 NA NA 3 9 NA 2 # 44
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3 138 13 147 NA NA 3 9 NA 2 # 45
8 132 4 66 NA NA 2 8 NA 2 # 46
10 164 6 166 NA NA 2 8 NA 2 # 47
6 124 5 121 NA NA 2 8 NA 2 # 48
13 164 10 161 NA NA 2 9 NA 2 # 49
7 93 5 90 NA NA 2 9 NA 2 # 50
END
#Initial Values 
#chain 1
list(d=c( NA, 0,0,0,0,0,0,0,0), mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  
0,0,0,0,0))
#chain 2
list(d=c( NA, -1,1,-1,1,1,-1,-2,2), mu=c(-3, -3, -3, -3, -3,    -3, -3, -3, -3, -3,    -3, -3, -3, -3, -3,    -3, -3, -3, -3, -3,    -3, -3, -3, -3, -3,    -3, -3, 
-3, -3, -3,    -3, -3, -3, -3, -3,    -3, -3, -3, -3, -3,   -3, -3, -3, -3, -3,    -3, -3, -3, -3, -3))
#chain 3
list(d=c( NA, 2,-1,5,1,1,1,-1,-1), mu=c(-3, -3, -7, -3, -3,    -3, -3, -3, -3, -3,    -3, 1, 3,3, 3,    -3, -3, -3, -3, -3,    -3, 5, -3, -3, -3,    -3, -3, -3, 
-5, -3,    -3, -3, 5, -3, -3,    -3, 8, -3, -3, -3,   -3, 3, 3, 3, -3,    -3, 3, -3, -3, 3))
Thrombolytic Treatments: UME FE Model, Binomial Likelihood
# Binomial likelihood, logit link, unrelated mean effects model
# Fixed effects model 
model{                            # *** PROGRAM STARTS
for(i in 1:ns){                   # LOOP THROUGH STUDIES
    mu[i] ~ dnorm(0,.0001)        # vague priors for trial baselines
    for (k in 1:na[i])  {         # LOOP THROUGH ARMS
        r[i,k] ~ dbin(p[i,k],n[i,k])         # binomial likelihood
        logit(p[i,k]) <- mu[i] + d[t[i,1],t[i,k]]    # model for linear predictor
        rhat[i,k] <- p[i,k] * n[i,k]      # expected value of the numerators 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))  #Deviance contribution
          +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))   
      }
   resdev[i] <- sum(dev[i,1:na[i]])       # summed residual deviance contribution for this trial
  }   
totresdev <- sum(resdev[])        # Total Residual Deviance
for (k in 1:nt) { d[k,k] <- 0 }      # set effects of k vs k to zero
for (c in 1:(nt-1)) {        # priors for all mean treatment effects
    for (k in (c+1):nt)  { d[c,k] ~ dnorm(0,.0001) } 
  }  
}        # *** PROGRAM ENDS
# Data is the same as for network meta-analysis model
# Initial values
# chain 1
list(mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,
           0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0), 
d = structure(.Data = c(NA,0,0,0,0,0,0,0,0,    NA,NA,0,0,0,0,0,0,0,     NA,NA,NA,0,0,0,0,0,0,     NA,NA,NA,NA,0,0,0,0,0,    
NA,NA,NA,NA,NA,0,0,0,0,    NA,NA,NA,NA,NA,NA,0,0,0,    NA,NA,NA,NA,NA,NA,NA,0,0,   NA,NA,NA,NA,NA,NA,NA,NA,0,     
NA,NA,NA,NA,NA,NA,NA,NA,NA),  .Dim = c(9,9)) )
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